Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
18.60
-1.49 (-7.42%)
At close: Apr 28, 2026, 4:00 PM EDT
18.50
-0.10 (-0.54%)
Pre-market: Apr 29, 2026, 8:17 AM EDT
Aktis Oncology Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Market Capitalization | 1,028 | - | - | - | - |
| Enterprise Value | 813 | - | - | - | - |
| Debt / Equity Ratio | 0.06 | 0.06 | 0.05 | 0.13 | 0.01 |
| Debt / FCF Ratio | - | - | 1.01 | - | - |
| Net Debt / Equity Ratio | -1.15 | -1.15 | -1.16 | -0.81 | -0.97 |
| Net Debt / EBITDA Ratio | 2.98 | 2.98 | 5.65 | 2.51 | 6.57 |
| Net Debt / FCF Ratio | 2.92 | 2.92 | -23.96 | 2.50 | 6.21 |
| Asset Turnover | 0.02 | 0.02 | 0.01 | - | - |
| Quick Ratio | 7.30 | 7.30 | 15.85 | 15.74 | 24.38 |
| Current Ratio | 7.37 | 7.37 | 15.98 | 16.07 | 25.12 |
| Return on Equity (ROE) | -29.45% | -29.45% | -25.18% | -24.42% | - |
| Return on Assets (ROA) | -15.79% | -15.79% | -14.51% | -16.68% | - |
| Return on Capital Employed (ROCE) | -32.00% | -32.00% | -16.90% | -30.00% | -14.90% |
| Buyback Yield / Dilution | -32.23% | -15.53% | -14.46% | -18.90% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.